Klaus G Parhofer1, Ulrich Laufs. 1. Medical Department IV, Campus Grosshadern, Medical Center of the University of Munich, Munich, Germany; Department of Cardiology, University Hospital of Leipzig, Leipzig, Germany.
Abstract
BACKGROUND: Hypertriglyceridemia affects 15-20% of the adult population and is associated with overweight, metabolic syndrome, and diabetes mellitus. It is often discovered incidentally. METHODS: This review is based on pertinent publications retrieved by a selective literature search, including current guidelines on hypertriglyceridemia. RESULTS: Elevated triglyceride (TG) levels are causally linked to cardiovascular disease; TG levels above 1000 mg/dL (11.4 mmol/L) can induce acute pancreatitis. The individual risk of cardiovascular disease and of pancreatitis must be estimated in order to decide whether, and how, hypertriglyceridemia should be treated. Lifestyle modifications (cessation of alcohol consumption, reduced intake of rapidly metabolized carbohydrates), weight loss, and blood sugar control are the most effective ways to lower TG levels. The need to lower the low-density lipoprotein (LDL) concentration must be determined on the basis of the cardiovascular risk, independently of the success of the lifestyle changes. Few patients need specific drug treatment to lower the TG level. Fibrates can lower TG concentrations, but their efficacy in combination with statins has not been clearly shown in endpoint studies. A daily dose of 2-4 g omega-3 fatty acids can also lower TG levels. To date, only a single large-scale randomized, blinded trial has shown the efficacy of 4 g of eicosapentaenoic acid ethyl ester per day in lowering the risk in high-risk patients (number needed to treat = 21). Patients with the very rare purely genetic types of hypertriglyceridemia (familial chylomicronemia syndrome) should be treated in specialized outpatient clinics. CONCLUSION: Hypertriglyceridemia is causally linked to cardiovascular disease and pancreatitis. Lifestyle modifications play a paramount role in its treatment.
BACKGROUND:Hypertriglyceridemia affects 15-20% of the adult population and is associated with overweight, metabolic syndrome, and diabetes mellitus. It is often discovered incidentally. METHODS: This review is based on pertinent publications retrieved by a selective literature search, including current guidelines on hypertriglyceridemia. RESULTS: Elevated triglyceride (TG) levels are causally linked to cardiovascular disease; TG levels above 1000 mg/dL (11.4 mmol/L) can induce acute pancreatitis. The individual risk of cardiovascular disease and of pancreatitis must be estimated in order to decide whether, and how, hypertriglyceridemia should be treated. Lifestyle modifications (cessation of alcohol consumption, reduced intake of rapidly metabolized carbohydrates), weight loss, and blood sugar control are the most effective ways to lower TG levels. The need to lower the low-density lipoprotein (LDL) concentration must be determined on the basis of the cardiovascular risk, independently of the success of the lifestyle changes. Few patients need specific drug treatment to lower the TG level. Fibrates can lower TG concentrations, but their efficacy in combination with statins has not been clearly shown in endpoint studies. A daily dose of 2-4 g omega-3 fatty acids can also lower TG levels. To date, only a single large-scale randomized, blinded trial has shown the efficacy of 4 g of eicosapentaenoic acid ethyl ester per day in lowering the risk in high-risk patients (number needed to treat = 21). Patients with the very rare purely genetic types of hypertriglyceridemia (familial chylomicronemia syndrome) should be treated in specialized outpatient clinics. CONCLUSION:Hypertriglyceridemia is causally linked to cardiovascular disease and pancreatitis. Lifestyle modifications play a paramount role in its treatment.
Authors: H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher Journal: N Engl J Med Date: 2018-11-07 Impact factor: 91.245
Authors: Theingi Aung; Jim Halsey; Daan Kromhout; Hertzel C Gerstein; Roberto Marchioli; Luigi Tavazzi; Johanna M Geleijnse; Bernhard Rauch; Andrew Ness; Pilar Galan; Emily Y Chew; Jackie Bosch; Rory Collins; Sarah Lewington; Jane Armitage; Robert Clarke Journal: JAMA Cardiol Date: 2018-03-01 Impact factor: 14.676
Authors: Robert A Hegele; Henry N Ginsberg; M John Chapman; Børge G Nordestgaard; Jan Albert Kuivenhoven; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Olivier S Descamps; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Luis Masana; Päivi Pajukanta; Klaus G Parhofer; Frederick J Raal; Kausik K Ray; Raul D Santos; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen; Gerald F Watts; Olov Wiklund Journal: Lancet Diabetes Endocrinol Date: 2013-12-23 Impact factor: 32.069
Authors: Alexander Folwaczny; Elisa Waldmann; Julia Altenhofer; Kerstin Henze; Klaus G Parhofer Journal: Nutrients Date: 2021-05-20 Impact factor: 5.717